FindTrial
Sign In

Prospective Evaluation of the Use of PET-CT in Hepatocarcinoma

Prospective Evaluation of the Use of PET-CT with 18 F -PSMA in Hepatocarcinoma: Comparison With Conventional Morphological Methods and Impact on Management Change

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-3vxgjsj
Enrollment
Unknown
Registered
2023-07-12
Start date
2023-01-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Unicentric study, with prospective data collection, which will be developed in the Nuclear Medicine Sector of the Image Department of AC Camargo Cancer Center. A total of 30 patients diagnosed with es
E01.370.350.350.800.700.500

Sponsors

Fundação Antônio Prudente - AC Camargo Cancer Center
Lead Sponsor
Fundação Antônio Prudente - AC Camargo Cancer Center
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: A total of 30 patients diagnosed with established hepatocellular carcinoma will be prospectively included and analyzed with the 18F-PSMA (Fluorine-18 Prostate specific Membrane Antigen) PET/CT (Positron emission tomography) study

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Evaluate the anomalous concentration of 18F-PSMA in the primary site (liver) as well as in secondary sites (metastases) Using the quantitative method with numerical measurement of the suv (standard uptake value) of the target lesions and jointly the qualitative analysis (visual comparison with normal biodistribution areas).—

Secondary

MeasureTime frame
Secondary outcomes are not expected.—

Countries

Brazil

Contacts

Public ContactMarcelo Cavicchioli

AC Camargo Cancer Center

marcelo.cavicchioli@accamargo.org.br+55 011 2189-5000 Ramal2832

Outcome results

None listed

Source: REBEC (via WHO ICTRP)